Sabby Management’s Lisata Therapeutics LSTA Stock Holding History

Sabby Management’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-68,462	Closed	-$173K	–	114
2022 Q4	$173K	Buy	68,462 +4,954	+8%	+$18.2K	0.15%	54
2022 Q3	$294K	Sell	63,508 -92,758	-59%	-$673K	0.37%	53
2022 Q2	$1.24M	Sell	156,266 -1,836	-1%	-$15.1K	0.85%	21
2022 Q1	$1.48M	Buy	158,102 +50,974	+48%	+$583K	0.22%	29
2021 Q4	$1.35M	Buy	107,128 +43,512	+68%	+$672K	0.2%	65
2021 Q3	$1.16M	Buy	+63,616	New	+$1.25M	0.16%	80
2021 Q2	–	Sell	-32,331	Closed	-$766K	–	180
2021 Q1	$936K	Buy	+32,331	New	+$980K	0.18%	83
2020 Q4	–	Sell	-6,400	Closed	-$152K	–	135
2020 Q3	$173K	Buy	+6,400	New	+$202K	0.03%	102
2015 Q3	–	Sell	-3,169	Closed	-$889K	–	394
2015 Q2	$889K	Buy	+3,169	New	+$1.18M	0.03%	225
2014 Q4	–	Sell	-76	Closed	-$63	–	267
2014 Q3	$63	Sell	76 -478	-86%	-$418K	﹤0.01%	241
2014 Q2	$542K	Buy	+554	New	+$539K	0.02%	186

Other funds holding LSTA

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMT

Founders Capital Management (Texas) Houston, Texas $205M AUM 41.7% 1-Year Est. Return

Sabby Management's LSTA Position: Q1 2023 in Review

Sabby Management sold out of Lisata Therapeutics (LSTA) in Q1 2023, closing a stake of 68,462 shares — an estimated $173K sold.

Sabby Management first reported a position in LSTA in Q2 2014 and held it in 11 quarters. The position peaked at $1.48M in Q1 2022. 21 funds tracked by Wall St. Rank hold LSTA as of Q1 2023.

Sabby Management reported no remaining Lisata Therapeutics position as of Q1 2023 after selling out during the quarter.
Sabby Management sold 68,462 Lisata Therapeutics shares in Q1 2023, an estimated $173K.
Sabby Management first reported a position in Lisata Therapeutics in Q2 2014 and held it in 11 quarters.
Sabby Management's Lisata Therapeutics position peaked at $1.48M in Q1 2022.
21 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2023.

Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.